1338P A phase III study comparing BCD-021, a bevacizumab biosimilar, and reference bevacizumab in patients with stage IIIB or IV non-squamous NSCLC

• DOI: 10.1016/j.annonc.2021.08.1939
• Publication Date: 2021-09-21T22:22:14Z
• Authors: N. Fadeeva; B. Roy; R. Nagarkar; H. Adamchuk; M. Matrosova; S. Tjulandin; D. Stroyakovskiy; D. Zhuravleva; G. Voevodin; M. Shustova; K.A. Kryukov; V. Chistiakov
• Keywords: Biosimilar